AstraZeneca shares are trading higher after the company announced the FDA accepted for review its sBLA for the self-administration of FLUMIST QUADRIVALENT.
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's shares are trading higher following the FDA's acceptance for review of its sBLA for the self-administration of FLUMIST QUADRIVALENT.
October 24, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's stock is trading higher due to the FDA's acceptance for review of its sBLA for FLUMIST QUADRIVALENT.
The FDA's acceptance for review of AstraZeneca's sBLA for the self-administration of FLUMIST QUADRIVALENT is a positive development for the company. This could potentially lead to increased sales and revenues for AstraZeneca, which is reflected in the increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100